IP Library Granted Patent US 7,250,299
Granted Patent B1
US 7,250,299 · App. 10/031,639 · Granted Jul 31, 2007

Method and means for producing high titer, safe, recombinant lentivirus vectors

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,250,299
App. No.
10/031,639
Granted
Jul 31, 2007
Kind
B1
Abstract

Lentiviral vectors modified at the 5′ LTR or both the 5′ and 3′ LTR are useful in the production of recombinant lentivirus vectors (See the Figure). Such vectors can be produced in the absence of a functional tat gene. Multiple transformation of the host cell with the vector carrying the transgene enhances virus production. The vectors can contain inducible or conditional promoters.

Claims (26)

1. A lentiviral vector system comprising a lentiviral packaging system and a lentiviral transfer vector comprising a heterologous gene operably linked to a regulatory element,

wherein the lentiviral packaging system comprises a structural lentiviral vector system comprising a first lentiviral vector that encodes a structural gene selected from a gag gene, a pol gene or both gag and pol genes; and a regulatory lentiviral vector comprising a rev gene, wherein the regulatory lentiviral vector is provided on a separate construct from the structural lentiviral vector system,

wherein the lentiviral transfer vector comprises a 5′ LTR and a 3′ LTR,

wherein the regulatory element is a heterologous regulatory element operable in a mammalian cell,

wherein a part or all of a regulatory element of the U3 region of the 5′ LTR is replaced by the heterologous regulatory element,

wherein a part or all of the U3 region of the 3′ LTR is replaced by a heterologous inducible regulatory element that is activated only in the presence of an activator expressed in trans, and

wherein the lentiviral vector system lacks a functional tat gene.

2. The lentiviral vector system of claim 1 , wherein the heterologous inducible regulatory element comprises a tet operator.

3. A method of producing a recombinant lentivirus comprising:

(a) transfecting a packaging host cell with the lentiviral vector system of claim 1 ; and

(b) recovering the recombinant lentivirus produced by the transfected packaging host cell.

4. The lentiviral vector system of claim 1 , wherein the regulatory lentiviral vector further comprises a heterologous regulatory element operably linked to the rev gene.

5. The lentiviral vector system of claim 1 , wherein the structural lentiviral vector system further comprises a regulatory response element (RRE) downstream of the structural gene.

6. The lentiviral vector system of claim 1 , wherein the structural lentiviral vector system further comprises a heterologous regulatory element operably linked to the structural gene.

7. The lentiviral vector system of claim 1 , wherein the tat gene is deleted.

8. The lentiviral vector system of claim 1 , wherein the tat gene is mutated.

9. The lentiviral vector system of claim 1 , which lacks a functional HIV env gene.

10. The lentiviral vector system of claim 1 , further comprising a viral env gene that is derived from a different virus than the structural genes.

11. The lentiviral vector system of claim 1 , which lacks functional vif, vpr, vpu and nef genes.

12. The lentiviral vector system of claim 1 , wherein the lentivirus is human immunodeficiency virus (HIV).

13. The lentiviral vector system of claim 2 , wherein the heterologous inducible regulatory element comprises seven copies of a tet operator (tet o 7).

14. The lentiviral vector system of claim 13 , wherein the tet o 7 is linked to a part of the 3′ U3 region that comprises a TATA box sequence.

15. The lentiviral vector system of claim 4 , wherein the heterologous regulatory element operably linked to the rev gene comprises a RSV U3 or a herpes simplex virus thymidine kinase (HSVtk) promoter.

16. The lentiviral vector system of claim 6 , wherein the heterologous regulatory element operably linked to the structural gene comprises a CMV promoter.

17. The lentiviral vector system of claim 10 , wherein the env gene is provided on a vector other than the first lentiviral vector.

18. The lentiviral vector system of claim 12 , wherein the HIV is HIV-1.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 29, 2019
From: MILTENYI BIOTEC GMBH
To: MILTENYI BIOTEC B.V. & CO. KG
Reel/Frame 051443/0669 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 26, 2018
From: MILTENYI BIOTEC TECHNOLOGY, INC.
To: MILTENYI BIOTEC GMBH
Reel/Frame 045035/0212 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 4, 2014
From: GBP IP, LLC
To: MILTENYI BIOTEC TECHNOLOGY, INC
Reel/Frame 033666/0185 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2008
From: CELL GENESYS, INC.
To: GBP IP, LLC
Reel/Frame 020666/0224 →